Kristie L. Kahl

Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.

Data from the phase 2 PECATI trial support the use of lenvatinib plus pembrolizumab as a potential standard treatment for patients with advanced B3-thymoma and thymic carcinoma.

Datopotamab deruxtecan was efficacious among patients with non-small cell lung cancer and baseline brain metastases who harbor actionable genomic alterations, according to an exploratory analysis of the phase 2 TROPION-Lung05 trial.

Retrospective data from the International Metastatic Renal Cell Carcinoma Database Consortium showed limited response rates in patients treated with tyrosine kinase inhibitors who received prior lenvatinib.

Tucidinostat plus R-CHOP demonstrated promising safety and efficacy outcomes in patients with previously untreated diffuse large B-cell lymphoma) expressing MYC and BCL-2.

Adagrasib significantly improved responses among patients with KRASG12C-mutated locally advanced or metastatic non–small cell lung cancer.

A higher dose of radiation therapy led to longer progression-free, cancer-specific, and overall survival, compared with the standard dose, in combination with long-term ADT in patients with high-risk prostate cancer.

The frontline use of pembrolizumab plus lenvatinib in patients with advanced HCC showed a 3-year or more response among 35% of responders; however, additional efficacy results remained consistent with previous findings from the phase 3 LEAP-002 trial.

Study findings support the use of a financial navigation program, in hopes to aid patients with multiple myeloma affected by financial toxicity.

Treatment with zanubrutinib, obinutuzumab, and venetoclax, also known as BOVen, showed promising safety and efficacy in treatment-naive patients with TP53-mutant mantle cell lymphoma.

Acalabrutinib-containing regimens continued to improve progression-free survival, especially when a complete response is obtained, compared with obinutuzumab plus chlorambucil, in treatment-naive patients with chronic lymphocytic leukemia, according to a 6-year follow-up.

In the final analysis of the phase 2 ELM-2 trial, odronextamab monotherapy showed encouraging efficacy, with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

According to extended follow-up of the phase 3 ALPINE trial, treatment with zanubrutinib continued to demonstrate improved progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

The retrospective analysis demonstrated comparable outcomes with teclistamab from the phase 2 MajesTEC-1 trial, highlighting the need for close monitoring and supportive care in patients treated for their relapsed or refractory multiple myeloma.

The RCC Cancer Immunity Cycle may inform the treatment and development of novel therapies in renal cell carcinoma moving forward.

Treatment with datopotamab deruxtecan led to a statistically significant and clinically meaningful improvement in progression-free survival in patients with metastatic hormone receptor-positive breast cancer.

The addition of nivolumab to frontline standard of care gemcitabine-cisplatin, followed by nivolumab maintenance therapy, led to statistically significant and clinically meaningful improvements in survival compared with gemcitabine-cisplatin alone in patients with unresectable or metastatic urothelial carcinoma.

The addition of pembrolizumab to enzalutamide did not improve survival compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer.

In the first phase 3 perioperative study of patients with resectable non–small cell lung cancer given adjuvant nivolumab after surgery and a prior regimen of nivolumab and chemotherapy showed improved event-free survival results.

Adding durvalumab to chemotherapy, followed by durvalumab and olaparib maintenance therapy improved progression-free survival in newly diagnosed advanced or recurrent endometrial cancer.

The addition of atezolizumab to chemotherapy improved progression-free survival in frontline advanced or recurrent endometrial carcinoma, in particular, among patients with deficient mismatch repair status.

Adding pembrolizumab to chemotherapy reduced the risk for disease recurrence, progression, complications, or death compared with chemotherapy alone in the treatment of triple-negative breast cancer.

Extending abemaciclib with endocrine therapy for 2 years continues to lower the risk of invasive disease and distant relapse in hormone receptor-positive, HER2-negative breast cancer, as demonstrated in the 5-year efficacy findings from the monarchE trial.

A single-arm trial induced high event-free and overall survival with the addition of durvalumab to standard of care before radical surgery in patients with muscle-invasive urothelial carcinoma.

Frontline treatment with AK112, a first-in-class humanized IgG1 bispecific antibody, plus chemotherapy demonstrated promising overall responses across 3 cohorts in a phase 2 trial.

Ziftomenib showed safety and efficacy in heavily pretreated patients with comutations and NPM1-mutated, relapsed/refractory acute myeloid leukemia.

The KMT2A inhibitor appeared safe and led to clinical activity in the treatment of patients with NPM1-mutated, relapsed/refractory acute myeloid leukemia, according to the phase 1 KOMET-001 trial.

Treatment with maintenance daratumumab, with or without pomalidomide, led to a median PFS of 28.5 months in patients with relapsed multiple myeloma after undergoing salvage autologous hematopoietic stem cell transplantation.

The phase 3 LUNAR trial evaluating tumor treating fields with standard-of-care therapies met its primary end point in patients with metastatic non–small cell lung cancer.